Passionate about IP! Since June 2003 the IPKat has covered copyright, patent, trade mark, designs, info-tech and confidentiality issues from a mainly UK and European perspective. Read, post comments and participate!

The team is Eleonora Rosati, Annsley Merelle Ward and Merpel. E-mail the Kats here!

The team is joined by GuestKats Söğüt Atilla, Oliver Fairhurst, Claire Gregg, Georgia Jenkins and Marcel Pemsel.

SpecialKats: Verónica Rodríguez Arguijo (TechieKat), Rose Hughes (PatKat) and Jocelyn Bosse (Book Review Editor).

InternKats: Wissam Bentazar, Simone Lorenzi and Kliment Markov.
Results for us patents
Strict US written description and enablement requirement applied to ADCs and platform inventions (Seagen v Daiichi Sankyo) Strict US written description and enablement requirement applied to ADCs and platform inventions (Seagen v Daiichi Sankyo) Reviewed by Dr Rose Hughes on Monday, December 08, 2025 Rating: 5
Alnylam v. Moderna and the judicious use of definitions: The European perspective Alnylam v. Moderna and the judicious use of definitions: The European perspective Reviewed by Dr Rose Hughes on Tuesday, June 10, 2025 Rating: 5
All to play for in CRISPR "first-to-invent" US patent battle as Federal Circuit instructs PTAB to reconsider (Regents v. Broad Institute, Nos. 22-1594, 22-1653) All to play for in CRISPR "first-to-invent" US patent battle as Federal Circuit instructs PTAB to reconsider (Regents v. Broad Institute, Nos. 22-1594, 22-1653) Reviewed by Dr Rose Hughes on Wednesday, May 28, 2025 Rating: 5
No back-pedaling on prosecution disclaimers (Azurity v. Alkem, Fed. Cir. Case No. 23-1977) No back-pedaling on prosecution disclaimers (Azurity v. Alkem, Fed. Cir. Case No. 23-1977) Reviewed by Dr Rose Hughes on Tuesday, April 22, 2025 Rating: 5
Don't shoot yourself in the foot: European file history in US patent claim interpretation (K-fee v Nespresso) Don't shoot yourself in the foot: European file history in US patent claim interpretation (K-fee v Nespresso) Reviewed by Dr Rose Hughes on Sunday, January 14, 2024 Rating: 5
CAFC reins in obvious-try-attack against dosage patent (Teva v Corcept) CAFC reins in obvious-try-attack against dosage patent (Teva v Corcept) Reviewed by Dr Rose Hughes on Monday, January 17, 2022 Rating: 5
Strict US written description requirement applied to CAR-T-cell therapy (Juno v Kite) Strict US written description requirement applied to CAR-T-cell therapy (Juno v Kite) Reviewed by Dr Rose Hughes on Sunday, January 09, 2022 Rating: 5
[Guest Post] Is this the end of patent claim construction as we know it? [Guest Post] Is this the end of patent claim construction as we know it? Reviewed by Peter Ling on Monday, July 20, 2020 Rating: 5
The patent debate surrounding PrEP, the game-changer in HIV prevention The patent debate surrounding PrEP, the game-changer in HIV prevention Reviewed by Dr Rose Hughes on Monday, September 02, 2019 Rating: 5
Subscribe to: Posts ( Atom )
Powered by Blogger.